Research programme: hydroxynorketamine derivatives - Spirify Pharma
Alternative Names: Hydroxynorketamine derivativesLatest Information Update: 28 Oct 2024
Price :
$50 *
At a glance
- Originator Spirify Pharma
- Class Analgesics; Antidepressants; Small molecules
- Mechanism of Action Amino acid modulators; Serine protease modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Depressive disorders; Pain
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for preclinical development in Depressive disorders in USA (PO)
- 28 Oct 2024 No recent reports of development identified for preclinical development in Pain in USA (PO)
- 01 Nov 2022 Spirify Pharma enters into a research collaboration with WeLab Barcelona to advance Spirify's proprietary class of analogs of hydroxynorketamine